基线因素与GRADE中的血糖结果的关联:比较有效性随机临床试验
W Timothy Garvey1, Robert M Cohen2, Nicole M Butera3
1Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL.
Diabetes care
|January 29, 2024
概括
年轻的年龄和较高的基线HbA1c预测2型糖尿病的血糖控制较差,但不会影响药物的有效性. 识别这些因素可以指导更积极的治疗策略.
科学领域:
- 内分泌学和新陈代谢学
- 临床糖尿病研究临床糖尿病研究
- 药物治疗 药物治疗
背景情况:
- 2型糖尿病的管理需要有效的降血糖策略.
- 甲胺是一种常见的第一线疗法,但通常需要额外的药物.
- 了解影响血糖控制的因素对于个性化治疗至关重要.
研究的目的:
- 检查与2型糖尿病的血糖结果相关的基线因素.
- 调查这些因素是否影响不同添加甲福林药物的有效性.
- 确定实现和维持目标HbA1c水平的预测因素.
主要方法:
- 糖尿病的血糖降低方法 (GRADE) 研究随机选择了5047名2型糖尿病患者接受基础胰岛素 (glargine),glimepiride,liraglutide或sitagliptin.
- 分析了基线因素与在第1年和第4年达到HbA1c<7.0%的相关性,使用回归和分类和回归树 (CART) 分析.
- 参与者被诊断为2型糖尿病的时间为10年以下,服用甲福明,HbA1c为6.8-8.5%.
主要成果:
- 年龄较小,西班牙裔种族,较高的基线HbA1c,禁食葡萄糖,甘油三,较低的胰岛素分泌和较高的胰岛素抵抗与较差的血糖结果有关.
- 没有任何基线因素预测到4年内格拉吉因,格莱梅皮里德,利拉格卢提德和西塔格利普丁之间的差异性有效性.
- 多变量分析显示,年轻的年龄和更高的基线HbA1c和禁食葡萄糖与血糖结果共同相关.
- 在CART分析中,年轻的年龄和基线HbA1c≥7.4%被确定为未能在4年内维持HbA1c<7%的预测因素.
结论:
- 基线因素在2型糖尿病中显著影响血糖控制,但不会改变研究药物的比较有效性.
- 年轻的年龄和较高的基线HbA1c是血糖恶化的关键预测因素.
- 识别患有低血糖控制风险的患者可以促进有针对性的,更积极的管理策略.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
128
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
128
01:15Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285
01:22Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204
01:15Diabetes: Symptoms, Diagnosis, and Complications
544
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
544
01:11Blinding
2.5K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.5K